By combining Mologic’s independently verified COVID-19 lateral flow test with BioSure’s market-leading design, the companies have created a self-test for COVID-19 that can be used without any training being required.
Mologic reports funding will be used by Mologic and global partners, to develop a point-of-need diagnostic test for the virus, in addition to supporting the Company to initiate research for novel vaccine candidates.
Mologic Announces Launch of Clinical Trial for Validation of Point-of-Care COPD Exacerbation Alert System
The the observational trial known as COPE-WEL has recently started recruitment of 263 patients across 10 centers in the UK.
Mologic Receives CE Mark Approval for PERiPLEX Diagnostic for Infection in Patients on Peritoneal Dialysis
Newly launched point-of-care test detects biomarkers of infection using lateral flow immunoassay Provides results in less than 10...